COVID-19 and Cardiovascular Disease
Kevin J Clerkin, Justin A Fried, Jayant Raikhelkar, Gabriel Sayer, Jan M Griffin, Amirali Masoumi, Sneha S Jain, Daniel Burkhoff, Deepa Kumaraiah, LeRoy Rabbani, Allan Schwartz, Nir Uriel, Kevin J Clerkin, Justin A Fried, Jayant Raikhelkar, Gabriel Sayer, Jan M Griffin, Amirali Masoumi, Sneha S Jain, Daniel Burkhoff, Deepa Kumaraiah, LeRoy Rabbani, Allan Schwartz, Nir Uriel
Abstract
Coronavirus disease 2019 (COVID-19) is a global pandemic affecting 185 countries and >3 000 000 patients worldwide as of April 28, 2020. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2, which invades cells through the angiotensin-converting enzyme 2 receptor. Among patients with COVID-19, there is a high prevalence of cardiovascular disease, and >7% of patients experience myocardial injury from the infection (22% of critically ill patients). Although angiotensin-converting enzyme 2 serves as the portal for infection, the role of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers requires further investigation. COVID-19 poses a challenge for heart transplantation, affecting donor selection, immunosuppression, and posttransplant management. There are a number of promising therapies under active investigation to treat and prevent COVID-19.
Keywords: COVID-19; cardiovascular diseases; pandemics; severe acute respiratory syndrome coronavirus 2.
Source: PubMed